KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Aquestive Therapeutics (AQST) Equity Average: 2018-2024

Historic Equity Average for Aquestive Therapeutics (AQST) over the last 7 years, with Dec 2024 value amounting to -$83.3 million.

  • Aquestive Therapeutics' Equity Average rose 5.19% to -$38.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$38.3 million, marking a year-over-year increase of 5.19%. This contributed to the annual value of -$83.3 million for FY2024, which is 25.95% up from last year.
  • Per Aquestive Therapeutics' latest filing, its Equity Average stood at -$83.3 million for FY2024, which was up 25.95% from -$112.5 million recorded in FY2023.
  • Aquestive Therapeutics' 5-year Equity Average high stood at -$27.3 million for FY2020, and its period low was -$112.5 million during FY2023.
  • For the 3-year period, Aquestive Therapeutics' Equity Average averaged around -$98.7 million, with its median value being -$100.3 million (2022).
  • Its Equity Average has fluctuated over the past 5 years, first slumped by 1,479.96% in 2020, then grew by 25.95% in 2024.
  • Over the past 5 years, Aquestive Therapeutics' Equity Average (Yearly) stood at -$27.3 million in 2020, then crashed by 139.17% to -$65.3 million in 2021, then slumped by 53.63% to -$100.3 million in 2022, then dropped by 12.13% to -$112.5 million in 2023, then rose by 25.95% to -$83.3 million in 2024.